TyRx Pharma

About TyRx Pharma

TyRx Pharma, Inc. operates as a developer and manufacturer of implantable combination drug and medical devices. The company was founded in 1998, stemming from the work of scientist Satish Pulapura at Rutgers University, who created a tyrosine-based polymer capable of slow-releasing antibiotics. This technology formed the scientific basis for TyRx's products.

The company's primary focus is on preventing surgical site infections (SSIs), particularly those associated with Cardiac Implantable Electronic Devices (CIEDs) like pacemakers and defibrillators. TyRx developed the AIGISRx Antibacterial Envelope, a mesh pouch designed to hold a CIED securely in place upon implantation. This envelope is unique because it also releases the antimicrobial agents rifampin and minocycline locally into the tissue for at least seven days, helping to reduce the risk of microbial colonization on the device.

TyRx commercialized its first-generation product in 2008, which was made from polypropylene. A significant milestone was the FDA clearance in 2013 for the AIGISRx R, a fully resorbable version of the envelope that the body absorbs in approximately nine weeks. The company also developed the AIGISRx N for use with spinal cord neuromodulators. The business model centers on selling these specialized medical devices to hospitals and healthcare providers for use during surgical procedures. The economic value lies in reducing the substantial costs associated with treating post-operative infections, which are estimated to cost the U.S. healthcare system over $1 billion annually for CIEDs.

In a major strategic move, Medtronic, Inc. acquired TyRx in January 2014 for an initial cash payment of $160 million, plus potential future milestone payments. This acquisition allowed Medtronic to integrate TyRx's infection control technology into its broader portfolio of cardiac and healthcare solutions. Under Medtronic's ownership, the technology continued to evolve, receiving further clearances and reaching a milestone of one million patients protected by 2023.